|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||318.501 g·mol−1|
|3D model (JSmol)|
CP 47,497 or (C7)-CP 47,497 is a cannabinoid receptor agonist drug, developed by Pfizer in the 1980s. It has analgesic effects and is used in scientific research. It is a potent CB1 agonist with a Kd of 2.1 nM.
On the 19th of January 2009, the University of Freiburg in Germany announced that an analog of CP 47,497 is the main active ingredient in the herbal "incense" product Spice, specifically the 1,1-dimethyloctyl homologue of CP 47,497. Both the dimethylheptyl and dimethyloctyl homologues were detected in different batches, with considerable variation in the concentration present in different samples that were analysed. The weaker dimethylhexyl and dimethylnonyl homologues were not found in any batches of smoking blends tested, but have been legally scheduled alongside the others in some jurisdictions, to forestall any potential use for this purpose. The 1,1-dimethyloctyl homologue of CP 47,497 is in fact several times more potent than the parent compound, which is somewhat unexpected as the 1,1-dimethylheptyl is the most potent substituent in classical cannabinoid compounds such as HU-210. The unapproved use of these compounds in herbal smoking blends has led to a resurgence in legitimate scientific research into their use, and consequently the C8 homologue of CP 47,497 has been assigned a proper name, cannabicyclohexanol.
CP 47,497 and its C6, C8, and C9 homologues were made illegal in France on 24 February 2009.
CP 47,497 and its C6, C8, and C9 homologues were made illegal in Latvia on 28 November 2009.
CP 47,497 and its C6, C8, and C9 homologues were made illegal in Lithuania on 5 June 2009.
CP 47,497 and its C6, C7, C8, and C9 homologues were made illegal in Sweden on 15 September 2009.
- Weissman A, Milne GM, Melvin LS (November 1982). "Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol". The Journal of Pharmacology and Experimental Therapeutics. 223 (2): 516–23. PMID 6290642.
- Shim JY, Welsh WJ, Howlett AC (2003). "Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction". Biopolymers. 71 (2): 169–89. doi:10.1002/bip.10424. PMID 12767117. S2CID 7909397.
- Roger Pertwee. Cannabinoids. Handbook of Experimental Pharmacology Volume 168. Springer. ISBN 3-540-22565-X
- Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR (December 1988). "Pharmacology and stereoselectivity of structurally novel cannabinoids in mice". The Journal of Pharmacology and Experimental Therapeutics. 247 (3): 1046–51. PMID 2849657.
- Hauptwirkstoff von „Spice“ identifiziert, University of Freiburg http://www.pr.uni-freiburg.de/pm/2009/pm.2009-01-19.19/
- "Warnung vor Räuchermischungen" [Warning for smoke mixtures]. Bundesamt für Sicherheit im Gesundheitswesen (Federal Office of Health Safety) (in German). 16 September 2009.
- Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreirós N (May 2009). "'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?". Journal of Mass Spectrometry. 44 (5): 832–7. Bibcode:2009JMSp...44..832A. doi:10.1002/jms.1558. PMID 19189348.
- Compton DR, Johnson MR, Melvin LS, Martin BR (January 1992). "Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents". The Journal of Pharmacology and Experimental Therapeutics. 260 (1): 201–9. PMID 1309872.
- Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, et al. (November 1991). "Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs". Pharmacology, Biochemistry, and Behavior. 40 (3): 471–8. doi:10.1016/0091-3057(91)90349-7. PMID 1666911. S2CID 19386120.
- Uchiyama N, Kikura-Hanajiri R, Matsumoto N, Huang ZL, Goda Y, Urade Y (February 2012). "Effects of synthetic cannabinoids on electroencephalogram power spectra in rats". Forensic Science International. 215 (1–3): 179–83. doi:10.1016/j.forsciint.2011.05.005. PMID 21640532.
- Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y (May 2010). "Chemical analysis of synthetic cannabinoids as designer drugs in herbal products". Forensic Science International. 198 (1–3): 31–8. doi:10.1016/j.forsciint.2010.01.004. PMID 20117892.
- "Bundesgetsetsplatz" (PDF). 21 January 2009.
- BGBl I Nr. 3 vom 21.01.2009, 22. BtMÄndV vom 19. Januar 2009, S. 49–50.
- "Version électronique authentifiée publiée au JO n° 0049 du 27/02/2009 - Legifrance". www.legifrance.gouv.fr.
- "Grozījumi Ministru kabineta 2005.gada 8.novembra noteikumos Nr.847 "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem"". LIKUMI.LV.
- "On the approval of lists of narcotic drugs and psychotropic substances". Regarding the Minister of Health of the Republic of Lithuania.
- Cook M (2011-02-28). "Synthetic marijuana illegal as of Tuesday". North County Times. San Diego. Archived from the original on 2011-03-03. Retrieved 2011-02-28.
- "Schedules of Controlled Substances: Temporary Placement of Five Synthetic Cannabinoids Into Schedule I". Federal Register. 1 March 2011.